http://www.daily. pk/7780/new- evidence- that-the- %e2%80%98swine- flu%e2%80% 99-p andemic-is-man- made/comment- page-1/#comment- 72 I added the following comment: Very little attention has been given to another lethal component included in MF-59, the oil-based adjuvant used in Novartis’ experimental vaccine, namely the glycoprotein GP120, which is also used in most experimental AIDS vaccines! According to Dr. Veljkovic’s assessment “the recombination hotspots in transgenic DNA may interact with the recombination signals flanking the V3 loop of the gp120 gene in AIDS vaccines to generate yet more exotic viruses”! The fact that the global population has been force-fed genetically modified food, containing antibiotic-resistan t marker genes and viral promoters such as the cauliflower mosaic virus (CaMV), which is closely related to the Hepatitis B and HIV virus and has a recombination “hotspot”, would effectively turn those receiving a vaccine containing a live virus and GP120 into “generators” of novel viral diseases never seen in mankind before. In addition, Novartis’ vaccines, such as OPTAFLU, for instance would also constitute a major scoop for the multi-billion dollar HIV/AIDS industry, as outlined in my article “Optaflu – look at the timeline” in 2007. http://www.healthy- humans.co. za/optaflu. html,since it may give false-positive results in serology tests using the ELISA method to detect antibodies against HIV-1, Hepatatis C and HTLV-1, which may be due to the IgM response to the vaccine. What a brilliant idea to inflate HIV statistics and push toxic antiretroviral drugs on healthy people, which no doubt happens on a daily basis in South Africa where 60 other diseases prevalent in Africa in addition to flu and pregnancy would also give a false-positive reading. http://www.emea. europa.eu/ humandocs/ PDFs/EPAR/ optaflu/H- 758-PI-en. pdf Please see Dr. Veljko Veljkovic’s assessment of gp120, which is also added to most experimental HIV vaccines and other vaccines injected into our kids: http://www.i- sis.org.uk/ isisnews/ i-sisnews11- 19.php The culprit viral gene The intended vaccines all contain gp120, a glycoprotein (protein decorated with side-chains of carbohydrates) belonging to the envelope of the human AIDS virus, HIV-1. The candidates include recombinant HIV proteins and peptides (subunit vaccines), HIV-1 or SIV (the monkey AIDS virus), killed or ‘attenuated’, ie, rendered harmless by successive passage in cultured cells, and a wide range of recombinant viral, bacterial and plasmid vectors expressing HIV proteins. (Plasmids are pieces of parasitic genetic material existing outside the cell’s genome, and are replicated by the cell independently of the cell’s genome.) HIV researchers Dr. Veljko Veljkovic and his colleagues in Belgrade Yugoslavia, have shown that the gp120, is similar to the part of human immunoglobulin (antibody) proteins (Ig) involved in binding foreign antigens, a crucial step in the immune response. Thus, any AIDS vaccine containing the gp120 glycoprotein or the gene coding for it could strongly interfere with the immune system and make the host more vulnerable to the virus. And in the longer term, it could accelerate disease progression in HIV patients that do not yet have symptoms. But the gp120 gene has other properties that pose an even greater threat to the vaccinated population. It contains ‘recombination hotspots’ similar to those in bacteria and viruses such as Haemophilus influenzae, Mycobacterium tuberculosis, hepatitis B virus and herpes simplex virus, that often co-infect with the HIV, and also similar to recombination elements found in immunoglobulin genes and oncogenes (genes associated with cancer) in the human host. Recombination hotspots are breakpoints at which genetic exchange or recombination occurs much more frequently than usual. Recombination of HIV with bacteria and viruses would generate new pathogens. Within the human host, recombination with human genes would promote chromosomal rearrangements and formation of abnormal immuno-globulins, thus undermining immune responses. HIV-1 sequences integrated into the genome can act as retrotransposons (jumping genes) that can mutate genes by jumping into them, and some of the mutations may trigger cancer [1]. Dr. Veljkovic’s team, in collaboration with researchers in UK, Italy and US, have already found evidence of recombination between gp120 and a gene from Haemophilus influenzae [2]. Recombination between an HIV gene and Mycoplasm fermentans has been implicated in ‘Gulf war syndrome’ [3] affecting a high proportion of soldiers from the United States and the United Kingdom who served in the Gulf war. A new subtype of HIV-1 may also have resulted from recombination between HIV-1 and SIV [4]. The proponents of the AIDS vaccination trials argue that the desperate situation precipitated by the AIDS epidemic justifies acceptance of the ‘small risks’ involved. But Veljkovic and his colleagues have written a monograph documenting the lack of efficacy of the vaccines and the enormous risks involved [5]. Not effective and dangerous In 1994, the AIDS Research Advisory Committee of the US National Institutes of Health (NIH) recommended that phase III clinical trials of gp120 vaccines should not be conducted “at this time and in this country”. The reasons, according to Dr. A. Fauci, director of National Institute of Allergy and Infectious Diseases (NIAID), were that the vaccines were ineffective; and there was a remote chance that the vaccines would compromise the immune system and make the recipient more vulnerable to infection [6]. The possibility that a vaccinated individual runs a greater risk of developing an established infection, or of progressing to disease more rapidly once infected, was confirmed subsequently [7]. The recombinant gp120 subunit vaccine tested in HIV-negative individuals was ineffective in protecting them against infection. Those who became infected during or after vaccination actually had in their blood sera significant levels of antibodies against the vaccine before they became infected, but those antibodies failed to protect them from infection. On the contrary, the vaccine appeared to have acted as a decoy to fool the immune system into mounting an attack on it, while allowing the HIV itself to slip through the host defence to get established. This subunit vaccine is due to go on Phase III clinical trial in Thailand. Live recombinant viral and bacterial vaccines The safety concerns for the individual are bad enough. But it is the effect on vulnerable populations that really worries Veljkovic and his colleagues, especially from the live recombinant viral and bacterial vector vaccines (see box). Many viral and bacterial pathogens are being used as vectors, and a number are currently considered promising AIDS vaccines. But they are also promising candidates for generating new infectious agents. Also refer to http://www.i- sis.org.uk/ AVWTU.php The gp120 protein is strongly immunogenic, which is why it is widely used in vaccines, in the hope that the body will produce antibodies against the protein and hence protect against the virus. But there have been many worrying signs that this may have just the opposite effect. For although the body mounts a strong immune reaction against the protein, and produces antibodies against it, those antibodies fail to protect against the virus. One main reason is that the virus is very mutable, and can readily mutate to escape immune detection. In addition, the immune reaction mounted against the original gp120 undermines the effectiveness of the immune system by over-stimulating it, so that it is less effective to cope with new infections. A recombinant gp120 vaccine tested in HIV-negative individuals in phaseI/II trails, was not effective in protecting against the disease. Not only that, participants in the trials had significant levels of circulating antibodies against the vaccine before they became infected, and came down with AIDS disease. The vaccine could also be dangerous. A vaccine based on the gp120 from the strain SF2, actually suppressed the production of antibodies that could neutralise the later infecting virus, while boosting the production of useless antibodies that were specific for the vaccine strain, SF2. In other words, gp120 acts as a molecular decoy to disarm the body’s antiviral response, leaving it more vulnerable, and increasing the likelihood of rapid disease progression in those vaccinated that later became infected. This phenomenon is called “deceptive imprinting” of the immune system. And he continues: First of all, the part of the gp120 molecule that plays the dominant role in provoking an immune response is the V3 loop. The V3 loop and flanking regions are similar in base sequence and structure to the antigen-binding region of the human immunoglobulin (Ig) (antibody protein). And it has been proposed since the early 1990s that this immunoglobulin- like domain in gp120 may interfere with the immune regulatory network. Another piece of evidence implicating genetic recombination is that the V3 loop and its flanking regions are located between recombination signals similar to those found in human immunoglobulins, and also similar to the Chi recombination hotpots found in many viruses and bacteria. Consequently, the immunologically dominant region of gp120 may be involved in recombining with human immunoglobulin genes resulting in autoimmune responses, and may also recombine with co-infecting viruses and bacteria to generate new pathogens. Evidence of such recombination has subsequently been found in the sera of AIDS patients.” Let me add to that another danger, namely the viral promoters such as the cauliflower mosaic virus (CaMV) used in genetic engineering and subsequently contained in GM feed and food. ” It is pertinent to point out that transgenic DNA in GM food and feed also carry recombination hotspots, such as the ones associated with the CaMV 35S promoter and the left and right borders of the Agrobacterium T-DNA used as vector to introduce transgenic DNA into the plant genome. These recombination hotspots enhance horizontal gene transfer and recombination. Furthermore, as Veljkovic said, the recombination hotspots in transgenic DNA may interact with the recombination signals flanking the V3 loop of the gp120 gene in AIDS vaccines to generate yet more exotic viruses.” Ingrid Blank/South Africa Comment by Ingrid Blank — August 1, 2009 @ 10:30 pm __._,_.___ Messages in this topic (1) Reply (via web post) | Start a new topic Messages | Files | Photos | Links | Database | Polls | Members | Calendar Change settings via the Web (Yahoo! ID required) Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe Recent Activity 118 New MembersVisit Your Group Give Back Yahoo! for Good Get inspired by a good cause. Y! Toolbar Get it Free! easy 1-click access to your groups. Yahoo! Groups Start a group in 3 easy steps. Connect with others. .. __,_._,___ -------------- next part -------------- An HTML attachment was scrubbed... URL: /pipermail/attachments/20090801/05727a22/attachment.html _______________________________________________ Biofuel mailing list Biofuel@sustainablelists.org http://sustainablelists.org/mailman/listinfo/sustainablelorgbiofuel Biofuel at Journey to Forever: http://journeytoforever.org/biofuel.html Search the combined Biofuel and Biofuels-biz list archives (70,000 messages): http://www.mail-archive.com/biofuel@sustainablelists.org/
